Clinical Trial Update: A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for Zenocutuzumab (MCLA-128) in solid tumors harboring NRG1 fusions, including non-small cell lung cancer and pancreatic cancer; t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Pancreatic Cancer

Drugs mentioned

• Zenocutuzumab (zenocutuzumab)

Snippet

Sponsor: Partner Therapeutics, Inc. | Conditions: Solid Tumours Harboring NRG1 Fusion, NSCLC Harboring NRG1 Fusion | Phase 2 | Status: ACTIVE_NOT_RECRUITING